Motley Fool Australia

Opthea Ltd (ASX: OPT) Share Price and News

Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)

() Chart and Price Data

.

Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range -
Days Range -
Turnover
As at

Fundamental Company Figures

Data provided by Morningstar.
Market Cap $769.87 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 337.66 million
Earnings per share -0.063
Dividend per share N/A
Year To Date Return -22.82%
Earnings Yield N/A
Franking N/A

Opthea Ltd (ASX: OPT) Latest News

Share price plummet

Why Cleanaway, Crown, Opthea, & Zoono shares are sinking lower today

More »

wooden blocks with percentage signs being built into towers of increasing height

2 exciting ASX mid cap ASX growth shares to buy for the long term

More »

Doctor pressing digitised screen with array of icons including one entitled health insurance

2 exciting ASX healthcare shares to buy for the long term

More »

Opthea share price bounces with Nasdaq listing on the cards

More »

woman in lab coat conducting testing representing mesoblast share price

Opthea share price surges higher on FDA news

More »

$100 notes multiplying into the future representing asx growth shares

Why Opthea shares could offer big growth potential

More »

Why the Opthea share price surged more than 20% today

More »

Investor riding a rocket blasting off over a share price chart

Why these 9 ASX shares have doubled in value in the past year

More »

Recent Stock Announcements

Price Sensitive Only$An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Show All
Date Heading $An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security. Time Pages File Size
 

About Opthea Ltd (ASX: OPT)

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatmentof eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Share Price History

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Dec 2020 $2.28 $-0.02 -0.87% 225,429 $2.30 $2.31 $2.25
02 Dec 2020 $2.30 $0.00 0.00% 272,930 $2.29 $2.31 $2.26
01 Dec 2020 $2.30 $0.00 0.00% 426,316 $2.30 $2.32 $2.24
30 Nov 2020 $2.30 $0.02 0.88% 794,445 $2.31 $2.34 $2.21
27 Nov 2020 $2.28 $0.01 0.44% 195,583 $2.28 $2.32 $2.26
26 Nov 2020 $2.27 $-0.05 -2.16% 303,565 $2.32 $2.35 $2.26
25 Nov 2020 $2.32 $0.01 0.43% 350,362 $2.36 $2.36 $2.31
24 Nov 2020 $2.31 $-0.03 -1.28% 663,351 $2.35 $2.38 $2.30
23 Nov 2020 $2.34 $0.06 2.63% 665,226 $2.28 $2.38 $2.25
20 Nov 2020 $2.28 $0.02 0.88% 400,237 $2.29 $2.31 $2.27
19 Nov 2020 $2.26 $0.05 2.26% 1,944,239 $2.22 $2.27 $2.19
18 Nov 2020 $2.21 $0.03 1.38% 3,540,986 $2.18 $2.22 $2.17
17 Nov 2020 $2.18 $-0.02 -0.91% 1,075,729 $2.19 $2.21 $2.14
16 Nov 2020 $2.20 $0.00 0.00% 91,733 $2.22 $2.24 $2.20
13 Nov 2020 $2.20 $0.05 2.33% 479,781 $2.18 $2.21 $2.17
12 Nov 2020 $2.15 $0.01 0.47% 837,871 $2.15 $2.22 $2.15
11 Nov 2020 $2.14 $-0.08 -3.60% 1,085,547 $2.22 $2.22 $2.13
10 Nov 2020 $2.22 $0.02 0.91% 1,491,409 $2.25 $2.26 $2.20
09 Nov 2020 $2.20 $-0.02 -0.90% 927,933 $2.22 $2.25 $2.18
06 Nov 2020 $2.22 $-0.01 -0.45% 543,067 $2.23 $2.23 $2.17
05 Nov 2020 $2.23 $-0.01 -0.45% 649,713 $2.24 $2.25 $2.18
04 Nov 2020 $2.24 $0.05 2.28% 597,736 $2.21 $2.26 $2.15
03 Nov 2020 $2.19 $-0.01 -0.45% 3,790,310 $2.16 $2.22 $2.16
Show more


Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Mr Lawrence Gozlan Non-Executive Director Jul 2020
Dr Megan Baldwin Chief Executive Officer,Managing Director Feb 2014
Mr Michael Sistenich Non-Executive Director Nov 2015
Mr Daniel Spiegelman Non-Executive Director Sep 2020
Dr Jeremy Levin Non-Executive Director Oct 2020
Mr Michael Tonroe Chief Financial Officer,Company Secretary May 2014
Michael Tonroe Chief Financial Officer,Company Secretary
Show more

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 53,144,712 19.74%
HSBC Custody Nominees (Australia) Limited GSCO ECA 29,682,673 11.03%
J P Morgan Nominees Australia Pty Limited 24,030,161 8.93%
Jagen Pty Ltd 13,520,540 5.02%
Armada Trading Pty Limited 13,332,031 4.95%
Hsbc Custody Nominees (Australia) Limited 13,180,132 4.90%
National Nominees Limited 10,706,431 3.98%
Bnp Paribas Noms Pty Ltd 9,821,245 3.65%
UBS Nominees Pty Ltd 8,146,658 3.03%
HSBC Custody Nominees (Australia) Limited A/C 2 7,741,513 2.88%
Cs Third Nominees Pty Limited 6,851,786 2.55%
Mrs Margaret Lynette Harvey 4,000,000 1.49%
Cs Fourth Nominees Pty Limited 2,737,539 1.02%
LL Family Nominees Pty Ltd 2,150,538 0.80%
Just Group Investment Pty Ltd 2,123,239 0.79%
Montoya Pty Limited 1,877,357 0.70%
Merrill Lynch (Australia) Nominees Pty Limited 1,555,260 0.58%
Bnp Paribas Nominees Pty Ltd 1,315,451 0.49%
Sandhurst Trustees Ltd 1,227,991 0.46%
LGL Trustees Limited 1,219,693 0.45%
Show more